GSK buys US Vaccine Firm for $3.3bn

GlaxoSmithKline on Tuesday bought Affinivax, a US biopharmaceutical firm for up to $3.3 billion, expanding further into vaccines before the demerger of its consumer health care arm.

The London-listed company has agreed to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones for Affinivax.

According to GSK, “the proposed acquisition further strengthens our vaccines research and development (R&D) pipeline, provides access to a new, potentially disruptive technology, and broadens GSK’s existing scientific footprint in the Boston area,” said GSK’s chief scientific officer Hal Barron.

“We look forward to working with the many talented people at Affinivax to combine our industry-leading development, manufacturing, and commercialisation capabilities to make this exciting new technology available to those in need,”

The acquisitions come as Chief Executive Emma Walmsley seeks to reshape GSK after she faced fierce investor criticism over the company’s delay in producing Covid jabs and treatments.

Glaxo last month bought US group Sierra Oncology, a specialist in medicines for rare forms of cancer, for $1.9 billion.

Meanwhile, GSK is in the process of demerging its consumer health care arm Haleon — a joint venture with US peer Pfizer — to concentrate on its main pharmaceutical business.

Source: GSK buys US Vaccine Firm for $3.3bn – StocksWatch (stocksng.com)


Notice: Function WP_List_Util::pluck was called incorrectly. Values for the input array must be either objects or arrays. Please see Debugging in WordPress for more information. (This message was added in version 6.2.0.) in /home/fundidqj/fundvinesecurities.com/securities/wp-includes/functions.php on line 6031

Related Posts

03

Nov
Business & Economy

ELITE WEALTH PLACEMENT FUND

Welcome to the Elite Wealth Placement Fund – a bespoke investment vehicle designed exclusively for high-net-worth individuals seeking attractive and tailored placement opportunities. Our fund is managed by a team of seasoned financial experts with a proven track record of delivering superior returns, while prioritizing risk management and long-term wealth preservation. As an exclusive member, you will […]

03

Nov
Business & Economy

PZ Cussons Nigeria Plc reports N113bn revenue, boosts profit after tax by 114% in one year

The Audited Financial Statement of PZ Cussons for the year ended 31 May 2023 show significant growth in the Company’s bottom line figures with 114% growth in its profit after tax for the 12 months period. The Group reported revenue of N113.964 billion for the 12 months period, up by 14.53% from N99.503 reported the previous year.[…]